Cleave Biosciences Receives $42,000,000 Series A Financing Round
- Feed Type
- Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=7f8326ed-17ca-43d6-b0c8-cd1f62c2d45b&Preview=1 - Date
10/11/2011 - Company Name
Cleave Biosciences - Mailing Address
Undisclosed Burlingame, CA 94010 - Company Description
The big idea at Cleave is to develop small-molecule chemical compounds that will interact with certain protein pathways that get thrown out of whack in patients with cancer. - Website
Undisclosed
- Transaction Type
Venture Equity - Transaction Amount
$42,000,000 - Transaction Round
Series A - Proceeds Purposes
None of Cleave’s drug candidates are ready yet for clinical trials, but the financing will give the company three to four years of operating cash to pursue that goal. - M&A Terms
- Venture Investor
Clarus Ventures - Venture Investor
U.S. Venture Partners - Venture Investor
5AM Ventures - Venture Investor
Astellas Venture Management - Venture Investor
OrbiMed
